SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Versicor (VERS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (68)5/24/2004 12:32:32 PM
From: Arthur Radley  Read Replies (1) of 83
 
Yes! I listned to the CC. Horner was very brief...stated they were working close with FDA and that the FDA was eager to work with them to resolve these issues. What was interesting was the question as to why Merck got approval when apparently the MICU data was stronger for this indication. Seems the MRK NDA was for different indication and candisas(sp) was merely a secondary indication. However, if the FDA approved the MRK drug for this indication, then why not the MICU "if" the data was more supportive.
IMO this down turn is overdone, since they should have additional Phase III data this fall. I jumped in around $12.50...hoping for a bounce.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News